Article Sidebar
Views PDF: 256
A STUDY ON CHANGE OF NT-PROBNP CONCENTRATION IN OBESE HEART FAILURE PATIENTS
Main Article Content
Abstract
Background: NT-proBNP is a test used to diagnose and evaluate the severity of heart failure. Overweight and obesity in patients with heart failure may alter NT-proBNP levels, resulting in impaired diagnosis and treatment of heart failure. Research is needed on the effect of overweight and obesity on NT-proBNP levels in patients with heart failure. Objectives: To describe the change of NT-proBNP concentration between 2 groups of heart failure patients with and without overweight and obesity. Methods: A retrospective, cross-sectional study with analysis performed on heart failure patients admitted to the cardiology department at Ho Chi Minh City University of Medicine and Pharmacy Hospital, campus 1 from September 2018 to May 2022. Results: 276 patients were recruited, including 129 men and 147 women. Mean age was 68. The median concentration of NT-proBNP in overweight and obesity heart failure patients and non obesity heart failure patients respectively 4933 (2112-11720) (pg/ml) and 3177 (1409-5927) (pg/ml) (p<0,001). The median concentration of NTproBNP by gender in the overweight and obese group in men was 2547 (1276-4574)(pg/ml) lower than the non-obese group in men by 3427 (1796-9892) (pg/ml) (p= 0.029). The median concentration of NT-proBNP according to overweight and obese women was 4039 (1414-8192) (pg/ml) and non-obese women was 4498 (2672-16191)(pg/ml) (p<0.028). This difference was statistically significant in both two genders. A statistically significant differences were also found in the concentration of NT-proBNP within the overweight and obese groups between men and women with (p=0.024). The concentration of NT-proBNP by age in the overweight and obese group at the age of 50 - 75 was 3151 (1575-6812) (pg/ml) and ≥ 75 was 3156 (1074-4975) (pg/ml) lower. the non-obese group at the age of 50 - 75 was 4988 (2066-10383) and ≥ 75 was 4343 (2435-16488) this difference was statistically significant with p<0.05. Conclusion: Plasma NT-proBNP concentrations in overweight and obese heart failure patients were lower than in non-obese heart failure patients according to gender and age groups. This is meaningful in adjusting the diagnosis and assessment of the patient's heart failure to agree with the patient's overweight and obesity status.
Article Details
Keywords
NT-proBNP, heart failure, obesity, biomarker
References
2. Alan S Go, Dariush Mozaffarian, Véronique L Roger, et al, (2014), "Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association", Circulation, 129 (3), pp. 399-410.
3. Global Initiative for Chronic Obstructive Lung Disease, (2011), Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, Global Initiative for Chronic Obstructive Lung Disease, pp.
4. Sandeep R Das, Mark H Drazner, Daniel L Dries, Gloria L Vega, et al, (2005), "Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study", Circulation, 112 (14), pp. pp. 2163-2168.
5. Tamara B Horwich, Michele A Hamilton, Gregg C Fonarow, (2006), "B-type natriuretic peptide levels in obese patients with advanced heart failure", J Am Coll Cardiol, 47 (1), pp. 85-90.
6. Vibhu Parcha, Nirav Patel, Rajat Kalra, et al, (2021), "Obesity and Serial NT-proBNP Levels in Guided Medical Therapy for Heart Failure With Reduced Ejection Fraction: Insights From the GUIDE-IT Trial", J Am Heart Assoc, 10 (7), pp. e018689.